Cancer Causes and Controversies: Understanding Risk Reduction and Prevention

Cancer Causes and Controversies: Understanding Risk Reduction and Prevention

Volumn , Issue , 2011, Pages 1-242

  Kwabi Addo, Bernard ^a   Lindstrom, Tia Laura ^b  

^a HOWARD UNIVERSITY   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863914932     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (473)

1. Mackay J, Jemal A, Lee NC, Parkin DM. 2006. The history of cancer. The Cancer Atlas. American Cancer Society, Atlanta, GA.
2. American Association for Cancer Research. Landmarks in Cancer Research. http:// www.aacr.org/home/about-us/centennial/landmarks-in-cancer-research.aspx (accessed Apr. 10, 2011).
3. National Cancer Institute. 2010. Cancer topics: Defining cancer. http://www.cancer. gov/cancertopics/cancerlibrary/what-is-cancer (accessed Apr. 10, 2011).
4. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell, 100, 57-70.
5. Crick F. 1970. Central dogma of molecular biology. Nature, 227, 561-3.
6. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. 1994. The Molecular Biology of the Cell. 3rd ed. New York: Garland Publishing Inc.
7. Leppert JT, Shvarts O, Kawaoka K, Lieberman R, Belldegrun AS, Pantuck AJ. 2006. Prevention of bladder cancer: a review. Eur Urol, 49, 226-34.
8. Cohen SM, Johansson SL. 1992. Epidemiology and etiology of bladder cancer. Urol Clin North Am, 19, 421-8.
9. Bjerregaard BK, Raaschou-Nielsen O, Sorensen M, et al. 2006. Tobacco smoke and bladder cancer·in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer, 119, 2412-6.
10. Stern MC, Umbach DM, Lunn RM, Taylor JA. 2002. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev, 11, 939-43.
11. Cancer Research UK. 2010. News & resources: Bladder cancer risk factors. http://info. cancerresearchuk.org/cancerstats/types/bladder/riskfactors/ (updated Jun. 25, 2010, accessed Apr. 11, 2011).
12. Chiou HY, Chiou ST, Hsu YH, et al. 2001. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasisendemic area in northeastern Taiwan. Am J Epidemiol, 153, 411-8.
13. Geoffroy-Perez B, Cordier S. 2001. Fluid consumption and the risk of bladder cancer: results of a multicenter case-control study. Int J Cancer, 93, 880-7.
14. Josephy P D and Mannervik B. 2006. Molecular toxicology. 2nd ed. New York: Oxford University Press.
15. National Cancer Institute. Cancer topics: Bladder cancer. http://www.cancer.gov/cancertopics/ types/bladder (accessed Apr. 10, 2011).
16. Kogevinas M, Ât Mannetje A, Cordier S, et al. 2003. Occupation and bladder cancer among men in Western Europe. Cancer Cause Control, 14, 907-14.
17. McKinney PA. 2005. Central nervous system tumours in children: epidemiology and risk factors. Bioelectromagnetics, Suppl 7, S60-S68.
18. Farrell CJ, Plotkin SR. 2007. Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. Neurol Clin, 25, 925-46.
19. Alexander V. 1991. Brain tumor risk among United States nuclear workers. Occup Med, 6, 695-714.
20. Davis FS. 2007. Epidemiology of brain tumors. Expert Rev Anticancer Ther, 7 (suppl), S3-S6.
21. Huang K, Whelan EA, Ruder AM, et al. 2004. Reproductive factors and risk of glioma in women. Cancer Epidemiol Biomarkers Prev, 13, 1583-8.
22. McKinley BP, Michalek AM, Fenstermaker RA, Plunkett RJ. 2000. The impact of age and sex on the incidence of glial tumors in New York State from 1976 to 1995. J Neurosurg, 93, 932-9.
23. Kley N, Whaley J, Seizinger BR. 1995. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function. Glia, 15, 297-307.
24. Reuss D, von Deimling A. 2009. Hereditary tumor syndromes and gliomas. Recent Results Cancer Res, 171, 83-102.
25. Wrensch M, Weinberg A, Wiencke J, et al. 1997. Does prior infection with varicellazoster virus influence risk of adult glioma? Am J Epidemiol, 145, 594-7.
26. Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, Schlehofer JR. 2006. Lack of association of herpesviruses with brain tumors. J Neurovirol, 12, 90-9.
27. Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr. 2006. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma, 6, 399-402.
28. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. 2002. Epidemiology of primary brain tumors: current concepts and review of the literature. Neurol Oncol, 4, 278-99.
29. National Brain Tumor Society. Tumor types. http://www.braintumor.org/patientsfamily-friends/about-brain-tumors/tumor-types/ (accessed Apr. 10, 2011).
30. Ha M, Im H, Lee M, et al. 2007. Radio-frequency radiation exposure from AM radio transmitters and childhood leukemia and brain cancer. Am J Epidemiol, 166, 270-9.
31. Preston DL, Ron E, Yonehara S, et al. 2002. Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J Natl Cancer Inst, 94, 1555-63.
32. Silvera SA, Miller AB, Rohan TE. 2006. Hormonal and reproductive factors and risk of glioma: a prospective cohort study. Internal J Cancer, 118, 1321-4.
33. Bachinski LL, Olufemi S, Zhou X, et al. 2005. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res, 65, 427-431.
34. Grant R, Ironside JW. 1995. Glutathione S-transferase and cytochrome P450 detoxifying enzyme distribution in human cerebral glioma. J Neuro Oncol, 25, 1-7.
35. Bondy ML, Wang, LE, El-Zein R, et al. 2001. Gamma-radiation sensitivity and risk of glioma. J Natl Cancer Inst, 93, 1553-7.
36. Blot WJ, Henderson BE, Boice JD Jr. 1999. Childhood cancer in relation to cured meat intake: review of the epidemiological evidence. Nutr Cancer, 34, 111-8.
37. McCredie M, Maisonneuve P, Boyle P. 1994. Perinatal and early postnatal risk factors for malignant brain tumors in New South Wales children. Int J Cancer, 56, 11-15.
38. Bluhm EC, Zahm SH, Fine HA, et al. 2007. Personal hair dye use and risks of glioma, meningioma, and acoustic neuroma among adults. Am J Epidemiol, 65, 63-71.
39. Davis JR, Brownson RC, Garcia R, et al. 1993. Family pesticide use and childhood brain cancer. Arch Environ Contam Toxicol, 24, 87-92.
40. Key T, Appleby P, Barnes I, Reeves G. 2002. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst, 94, 606-16.
41. Erlandsson G, Montgomery SM, Cnattingius S, Ekbom A. 2003. Abortions and breast cancer: record-based case-control study. Int J Cancer, 103, 676-9.
42. Land CE, Tokunaga M, Koyama K, et al. 2003. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res, 160, 707-17.
43. Wolff MS, Weston A. 1997. Breast cancer risk and environmental exposures. Environ Health Perspect, 105 (suppl 4), 891-6.
44. Kaufman DJ, Beaty TH, Struewing JP. 2003. Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes. Cancer Epidemiol Biomarkers Prev, 12, 1045-52.
45. Evans JP, Skrzynia C, Susswein L, Harlan M. 2005-2006.Genetics and the young woman with breast cancer. Breast Dis, 23, 17-29.
46. Tarone RE and Chu KC. 2002. The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States). Cancer Causes Control, 13, 7-14.
47. Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M. 2003. Trends in breast cancer by race and ethnicity. CA Cancer J Clin, 53, 342-55.
48. Sellers TA, Kushi LH, Cerhan JR, et al. 2001. Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology, 12, 420-8.
49. Brinton LA, Sherman ME, Carreon JD, Anderson WR. 2008. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst, 100, 1477-81.
50. Stark A, Kleer CG, Martin I, et al. 2010. African ancestry and higher prevalence of triple negative breast cancer findings from an international study. Cancer, 116, 4926-32.
51. Pinheiro SP, Holmes MD, Pollak MN, et al. 2005. Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev, 14, 2147-53.
52. Peters TM, Schatzkin A, Gierach GL. 2009. Physical activity and postmenopausal breast cancer risk in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev, 18, 289-96.
53. Holm LE, Callmer E, Hjalmer ML, et al. 1989. Dietary habits and prognostic factors in breast cancer. JNCI, 81, 1218-23.
54. Conlon MS, Johnson KC, Bewick MA, et al. 2010. Smoking (active and passive), Nacetyltransferase 2 and risk of breast cancer. Cancer Epi, 34, 142-9.
55. National Cancer Institute. Cancer topics: Breast cancer. http://www.cancer.gov/cancertopics/ types/breast (accessed Apr. 10, 2011).
56. Wright TC Jr., Schiffman M. 2003. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med, 348, 489-90.
57. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. 2003. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol, 157, 218-26.
58. Rigoni S. 1987. Statistical facts about cancers on which Doctor Rigoni-Stern based his contribution to the Surgeons’ Subgroup of the IV Congress of the Italian Scientists on 23 September 1842. (translation). Stat Med, 6, 881-4.
59. Scheffner M, Munger K, Byrne JC, Howley PM. 1991. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA, 88, 5523-7.
60. Cymet TC. 2006. Sexually activated or transmitted? Questions about HPV. J Am Osteopath Assoc, 106, 423.
61. Haverkos HW. 2004. Viruses, chemicals and co-carcinogenesis. Oncogene, 23, 6492-9.
62. Prokopczyk B, Cox JE, Hoffmann D, Waggoner SE. 1997. Identification of tobaccospecific carcinogen in the cervical mucus of smokers and nonsmokers. J Natl Cancer Inst, 89, 868-73.
63. Baldwin A, Huh KW, Munger K. 2006. Human papillomavirus E7 oncoprotein dysregulates steroid receptor coactivator 1 localization and function. J Virol, 80, 6669-77.
64. Hernandez BY, McDuffie K, Zhu X, et al. 2005. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol Biomarkers Prev, 14, 2550-6.
65. Leyden WA, Manos MM, Geiger AM, et al. 2005. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst, 97, 675-83.
66. Cox JT. 2006. Epidemiology and natural history of HPV. J Fam Pract, November (suppl), 3-9 Review.
67. Cason J, Rice P, Best JM. 1998. Transmission of cervical cancer-associated human papilloma virus from mother to child. Intervirology, 44, 213-8.
68. Haverkos HW. 2005. Multifactorial etiology of cervical cancer: a hypothesis. Med-GenMed, 7(4), 57.
69. Clarke EA, Anderson TW. 1979. Does screening by „PAP‰ smears help prevent cervical cancer? A case-control study. Lancet, 314, 1-4.
70. Lee M, Lin T-L, Horne DA. 2009. FDA statistical review and evaluation Gardasil efficacy. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedPro ducts/UCM190978.pdf (accessed Apr. 12, 2011).
71. GLOBOCAN. 2008. Cancer incidence and mortality. Prediction. World cervix uteri. http://globocan.iarc.fr/burden.asp?selection_pop=220900&Text-p=World& selection_cancer=4152&Text-c=Cervix+uteri&pYear=2&type=1&window=1&subm it=%A0Execute%A0 (accessed Apr. 10, 2011).
72. Potter JD. 1999. Colorectal cancer: molecules and populations. J Natl Cancer Inst, 91, 916-32.
73. Narayan S, Roy D. 2003. Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer, 2, 41.
74. Umar A, Kunkel TA. 1996. DNA-replication fidelity, mismatch repair and genome instability in cancer cells. Eur J Biochem, 238, 297-307.
75. Campos FG, Logullo Waitzberg AG, Kiss DR, Waitzberg DL, Habr-Gama A, Gama-Rodrigues J. 2005. Diet and colorectal cancer: current evidence for etiology and prevention. Nutr Hosp, 20, 18-25.
76. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. 2008. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther, 27, 104-19.
77. Peters U, Chatterjee N, McGlynn KA, et al. 2004. Calcium intake and colorectal adenoma in a U.S. colorectal cancer early detection program. Am J Clin Nutr, 80, 1358-65.
78. Hardman AE. 2001. Physical activity and cancer risk. Proc Nutr Soc, 60, 107-13.
79. Giovannucci E. 2001. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 10, 725-31.
80. National Cancer Institute. 2010. Cancer topics: What you need to know about cancer of the colon and rectum. http://www.cancer.gov/cancertopics/wyntk/colon-and-rectal/ page1 (accessed Apr. 2011).
81. Center MM, Jemal A, Smith RA, Ward E. 2009. Worldwide variations in colorectal cancer. CA Cancer J Clin, 59, 366-78.
82. Bandipalliam P. 2005. Syndrome of early onset colon cancers hematologic malignancies and feature of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutation. Familial Cancer, 4, 323-3.
83. Seitz HK, Maurer B, Stickel F. 2005. Alcohol consumption and cancer of the gastrointestinal tract. Dig Dis, 23, 297-303.
84. National Cancer Institute. 2010. Cancer topics: Colon and rectal cancer. http://www. cancer.gov/cancertopics/types/colon-and-rectal(accessed Apr. 9, 2011).
85. Goldman R and Shields PG. 2003. Food mutagens. J Nutr. 133 Suppl 3, 965S-73S.
86. Gao Y, Hu N, Han X, et al. 2009. Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China. BMC Cancer, 9, 269.
87. Engel LS, Chow WH, Vaughan TL, et al. 2003. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst, 95, 1404-13.
88. Souza RF, Spechler SJ. 2005. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin, 55, 334-51.
89. Risk JM, Mills HS, Garde J, et al. 1999. The tylosis esophageal cancer (TOC) locus: more than just a familial cancer gene. Dis Esophagus, 12, 173-6.
90. Hiyama T, Yoshihara M, Tanaka S, Chayama K. 2007. Genetic polymorphisms and esophageal cancer risk. Int J Cancer, 121, 1643-58.
91. Yu Y, Taylor PR, Li JY, et al. 1993. Retrospective cohort study of risk-factors for esophageal cancer in Linxian, People’s Republic of China. Cancer Causes Control, 4, 195-202.
92. Blot WJ, Li JY, Taylor PR, et al. 1993. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst, 85, 1483-92.
93. Yokoyama A, Muramatsu T, Ohmori T, Higuchi S, Hayashida M, Ishii H. 1996. Esophageal cancer and aldehyde dehydrogenase-2 genotypes in Japanese males. Cancer Epidemiol Biomarkers Prev, 5, 99-102.
94. Ghavamzadeh A, Moussavi A, Jahani M, Rastegarpanah M, Iravani M. 2001. Esophageal cancer in Iran. Semin Oncol, 28, 153-7.
95. Castellsague X, Munoz N, De SE, Victora CG, Castelletto R, Rolon PA. 2000. Influence of mate drinking, hot beverages and diet on esophageal cancer risk in South America. Int J Cancer, 88, 658-64.
96. World Health Organization, IARC, GLOBOCAN. 2008, Cancer incidence and mortality worldwide (prediction for esophageal cancer in 2010). http://globocan.iarc.fr/burden. asp?selection_pop=220900&Text-p=World&selection_cancer=19040&Text-c=Oes ophagus&pYear=2&type=1&window=1&submit=%A0Execute%A0 (accessed Apr. 9, 2011).
97. Kamangar F, Malekzadek R, Dawsey SM, et al. 2007. Esophageal cancer in northeastern Iran: a review. Arch Iranian Med, 10, 70-82.
98. Tryhus MR, Davis M, Griffith JK, et al. 1989. Familial achalasia in twin siblings: significance of possible hereditary role. J Pediatric Surg, 24, 292-5.
99. Goode EL, Ulrich CM, Potter JD. 2002. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev, 11, 1513-30.
100. Newberne PM. 1985. Dietary factors affecting biological responses to esophageal and colon chemical carcinogens. In: Xenobiotic Metabolism: Nutritional Effects. ACS Symposium Series, American Chemical Society; Vol. 277, Chapter 13, pp. 163-76.
101. Pandeya N, Williams G, Green AC, Webb PM, Whiteman DC. 2009. Alcohol consumption and the risk of adenocarcinoma and squamous cell cancer of esophagus, Gastroenterology, 136, 1155-7.
102. Lee J-M, Liu TY, et al. 2005. Safrole-DNA adducts in tissues from esophageal cancer patients: clues to areca-related esophageal carcinogenesis. Mutat Res, 565, 121-8.
103. Wei WQ, Abnet CC, Lu N, Roth MJ, Wang GQ, Dye BA, Dong ZW, Taylor PR, Albert P, Qiau YL, Dawsey SM. 2005. Risk factors for esophageal squamous dysplasia in adult inhabitants of a high risk region of China. Gut, 54, 759-63.
104. National Cancer Institute. Cancer topics: Esophageal cancer. http://www.cancer.gov/ cancertopics/types/esophageal (accessed Apr. 8, 2011).
105. Munitiz V, Parrilla P, Ortiz A, Matinez-de-Haro L, Yelamos J, Molina J. 2008. High risk of malignancy- familial Barrett’s esophagus: Presentation of one family. J of Clin Gastroenterolog. 42, 806-9.
106. Chu FS, Li GY. 1994. Simultaneous occurrence of fumonisin B-1 and other mycotoxins in mouldy corn collected from the Peoples Republic of China in regions with high incidences of esophageal cancer. Appl Environ Microbiol. 60, 847-52.
107. Makun HA, Anjorin ST, Moronfoye B, Adejo FO, Afolabi OA, Fagbayibo G, et al. 2010. Fungal and aflatoxin contamination of some human food commodities in Nigeria. Afr J Food Sci. 4, 127-35.
108. Graham S, Haughey B, Marshall J, et al. 1990. Diet in the epidemiology of gastric cancer. Nutr Cancer, 13, 19-34.
109. Alexander GA, Brawley OW. 2000. Association of Helicobacter pylori infection with gastric cancer. Mil Med, 165, 21-7.
110. Suzuki S, Muroishi Y, Nakanishi I, Oda Y. 2004. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer. J Gastroenterol, 39, 220-30.
111. Farthing MJ, Fitzgerald R, Zhang ZW. 2001. Acid, helicobacter and immunity: a new paradigm for oesophagogastric cancer. J Physiol Paris, 95, 423-7.
112. Mayne ST, Risch HA, Dubrow R, et al. 2001. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev, 10, 1055-62.
113. National Cancer Institute. 2010. Cancer topics: Stomach (gastric) cancer. http://www. cancer.gov/cancertopics/types/stomach (accessed Apr. 9, 2010).
114. El-Omar EM, Carrington M, Chow WH, et al. 2000. Interleukin-1 polymorphisms associated with increase risk of gastric cancer. Nature, 404, 398-402.
115. Figueiredo C, Machado JC, Pharoah P, et al. 2002. Helicobacter pylori and interluekin I genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst, 94, 1680-7.
116. Navarro Silvera SA, Mayne ST, Risch H, et al. 2008. Food group intake and risk of subtype of esophageal and gastric cancer. Int J Cancer, 123, 852-60.
117. Slotman GJ, Swaminathan AP, Rush BF Jr. 1983. Head and neck cancer in a young age group: High incidence in black patients. Head Neck Surg, 5, 293-8.
118. Ye H, Yu T, Temam S, et al. 2008. Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics, 9, 69.
119. Johnson N. 2001. Tobacco use and oral cancer: A global perspective. J Dent Educ, 65, 328-39.
120. Ragin CC, Modugno F, Gollin SM. 2007. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res, 86, 104-14.
121. Hashibe M, Brennan P, Benhamou S, et al. 2007. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst, 99, 777-89.
122. Wang Y, Spitz MR, Lee JJ, Huang M, Lippman SM, Wu X. 2007. Nucleotide excision repair pathway genes and oral premalignant lesions. Clin Cancer Res, 13, 3753-8.
123. An J, Liu Z, Hu Z, et al. 2007. Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev, 16, 1633-8.
124. Chen K, Hu Z, Wang LE, et al. 2007. Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res, 13, 4300-5.
125. Rossi M, Garavello W, Talamini R, et al. 2007. Flavonoids and the risk of oral and pharyngeal cancer: a case-control study from Italy. Cancer Epidemiol Biomarkers Prev, 16, 1621-5.
126. Wen X, Walle T. 2005. Preferential induction of CYP1B1 by benzo[a]pyrene in human oral epithelial cells: impact on DNA adduct formation and prevention by polyphenols. Carcinogenesis, 26, 1774-81.
127. Morse DE, Psoter WJ, Cleveland D, et al. 2007. Smoking and drinking in relation to oral cancer and oral epithelial dysplasia. Cancer Causes Control, 18, 919-29.
128. Kabat GC, Wynder EL. 1989. Type of alcoholic beverage and oral cancer. Int J Cancer, 43, 190-4.
129. Visapaa JP, Gotte K, Benesova M, et al. 2004. Increased cancer risk in heavy drinkers with the alcohol dehydrogenase 1C*1 allele, possibly due to salivary acetaldehyde. Gut, 53, 871-6.
130. Chen YC, Hunter DJ. 2005. Molecular epidemiology of cancer. CA Cancer J Clin, 55, 45-54.
131. Tezal M, Sullivan MA, Reid M E, et al. 2007. Chronic periodontitis and the risk of tongue cancer. Arch Otolaryngol Head Neck Surg, 133, 450-4.
132. Shavers VL, Harlan LC, Winn D, Davis WW. 2003. Racial/ethnic patterns of care for cancers of the oral cavity, pharynx, larynx, sinuses, and salivary glands. Cancer Metastasis Rev, 22, 25-38.
133. National Cancer Institute. 2010. SEER (Surveillance Epidemiology and End Results) data, stat fact sheet: Oral cavity and pharynx. http://www.seer.cancer.gov/statfacts/ html/oralcav.html (accessed March 27, 2011).
134. Egeli U, Ozkan L, Tunca B, et al. 2000. The relationship between genetic susceptibility to head and neck cancer with the expression of common fragile sites. Head Neck, 22, 591-8.
135. Reshmi S, Cand Gollin SM. 2005. Chromosomal instability in oral cancer cells. J Dent Res, 84, 107-17.
136. World Health Organization, IARC, GLOBOCAN Project. 2008. Cancer incidence and mortality worldwide in 2008 (with online analysis/prediction tables for future years) http://globocan.iarc.fr/ (accessed Apr. 9, 2011).
137. Legler JM, Ries LA, Smith MA, et al. 1999. Cancer surveillance series [corrected]: brain and other central nervous system cancers: Recent trends in incidence and mortality. J Natl Cancer Inst, 91, 1382-90.
138. Goldman M. 1982. Ionizing radiation and its risks. West J Med, 137, 540-7.
139. Belson M, Kingsley B, Holmes A. 2007. Risk factors for acute leukemia in children: a review. Environ Health Perspect, 115, 138-45.
140. Descatha A, Jenabian A, Conso F, Ameille J. 2005. Occupational exposures and haematological malignancies: overview on human recent data. Cancer Causes Control, 16, 939-53.
141. Morrissette JJ, Halligan GE, Punnett HH, McKenzie AS, Guerrero F, de Chadarevian JP. 2006. Down syndrome with low hypodiploidy in precursor B-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet, 169, 58-61.
142. Chang JS, Selvin S, Metayer C, Crouse V, Golembesky A, Buffler PA. 2006. Parental smoking and the risk of childhood leukemia. Am J Epidemiol, 163, 1091-100.
143. Tang D, Warburton D, Tannenbaum SR, et al. 1999. Molecular and genetic damage from environmental tobacco smoke in young children. Cancer Epidemiol Biomarkers Prev, 8, 427-31.
144. Fraga CG, Motchnik PA, Wyrobek AJ, Rempel DM, Ames BN. 1996. Smoking and low antioxidant levels increase oxidative damage to sperm DNA. Mutat Res, 351, 199-203.
145. Rauscher GH, Sandler DP, Poole C, et al. 2003. Is family history of breast cancer a marker of susceptibility to exposures in the incidence of de novo adult acute leukemia? Cancer Epidemiol Biomarkers Prev, 12, 289-94.
146. Grulich AE, Wan X, Law MG, et al. 2000. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin’s lymphoma in people with AIDS. AIDS, 14, 133-40.
147. Cannon M, Cesarman E. 2000. Kaposi’s sarcoma-associated herpes virus and acquired immunodeficiency syndrome-related malignancy. Semin Oncol, 27, 409-19.
148. Grulich AE, Vajdic CM, Cozen W. 2007. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev, 16, 405-8.
149. Chang ET, Smedby KE, Hjalgrim H, et al. 2005. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst, 97, 1466-74.
150. Landgren O, Zhang Y, Zahm SH, Inskip P, Zheng T, Baris D. 2006. Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev, 15, 2342-7.
151. Folley JH, Borges W, Yamawaki T. 1952. Incidence of leukemia in survivors of the atomic bomb in Hiroshima and Nagasaki, Japan. Am J Med, 13, 311-21.
152. Archer VE. 1987. Association of nuclear fallout with leukemia in the United States. Arch Environ Health, 42, 263-71.
153. Cantor KP, Strickland PT, Brock JW, et al. 2003. Risk of non-Hodgkin’s lymphoma and prediagnostic serum organchlorines. Environ Health Perspective, 111, 179-83.
154. George ED, Sadovsky R. 1999. Multiple myeloma: Recognition and management. Am Fam Physician, 59, 185-94.
155. Rubinsten MA. 1949. Multiple myeloma as a form of leukemia. Blood, 4, 1049-67.
156. Ries LAG, Eisner MP, Kosary CL et al. 2003. SEER cancer statistics review, 1975- 2000. Bethesda, MD. National Cancer Institute.
157. Lewis DR, Pottern LM, Brown LM, et al. 1994. Multiple myeloma among blacks and whites in the United States: The role of chronic antigenic stimulation. Cancer Causes Control, 5, 2547--54.
158. National Cancer Institute. 2010. Cancer topics: Leukemia. http://www.cancer.gov/ cancertopics/types/leukemia (accessed Apr. 9, 2011).
159. National Cancer Institute. 2010. Cancer topics: Hodgkin lymphoma. http://www.can cer.gov/cancertopics/types/hodgkin (accessed Apr. 9, 2011).
160. National Cancer Institute. 2010. Cancer topics: Non-Hodgkin lymphoma. http://www. cancer.gov/cancertopics/types/non-hodgkin (accessed Apr. 9, 2011).
161. Veldt BJ, Chen W, Heathcote EJ, et al. 2008. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology, 47, 1856-62.
162. Gurtsevitch VE. 2008. Human oncogenic viruses: Hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochemistry (Mosc), 73, 504-13.
163. Yamanaka T, Shiraki K, Nakazaawa S, et al. 2001. Impact of hepatitis B and C virus infection on the clinical prognosis of alcoholic liver cirrhosis. Anticancer Res, 21, 2937-40.
164. Peers FG, Linsell CA. 1973. Dietary aflatoxins and liver cancer-a population based study in Kenya. Br J Cancer, 27, 473-84.
165. Budhu A, Wang XW. 2006. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol, 80, 1197-213.
166. Yu MC, Yuan JM. 2004. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology, 127 (suppl 1), S72-S78.
167. Turner PC, Sylla A, Diallo MS, Castegnaro JJ, Hall AJ, Wild CP. 2002. The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: A basis for primary prevention in Guinea-Conakry, West Africa. J Gastroenterol Hepatol, 17 (suppl), S441-S448.
168. Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, Galle PR. 2007. Genetics of hepatocellular carcinoma. World J Gastroenterol, 13, 2271-82.
169. Jackson PE, Qian GS, Friesen MD, et al. 2001. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res, 61, 33-5.
170. Inoue M, Yoshimi I, Sobue T, Tsugane S. 2005. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst, 97, 293-300.
171. Gish RG. 2007. Improving outcomes for patients with chronic hepatitis B 19. Hepatol Res, 37 (suppl 1), S67-S78.
172. World Health Organization. 2011. Global alert and response, Hepatitis B. http://www.who. int/csr/disease/hepatitis/whocdscsrlyo20022/en/index1.html (accessed Apr. 9, 2011).
173. Richelle M, Tavazzi I, Offord E. 2001. Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. J Agric Food Chem, 49, 3438-42.
174. National Academy of Sciences. 2009. The hepatitis B story. http://www.beyonddiscovery. org/content/view.article.asp?a=265 (accessed Apr. 9, 2011).
175. International Agency for Research on Cancer; GLOBOCAN. 2008. Liver cancer incidence and mortality worldwide in 2008. http://globocan.iarc.fr/factsheets/cancers/ liver.asp(accessed Apr. 9, 2011).
176. International Agency for Research on Cancer; GLOBOCAN. 2008. Prediction. World cancer estimations for 2008 and 2010. http://globocan.iarc.fr/burden.asp?selection_ pop=220900&Text-p=World&selection_cancer=13070&Text-c=Liver&pYear=2&ty pe=0&window=1&submit=%A0Execute%A0 (accessed Apr. 9, 2011).
177. National Cancer Institute. 2010. Cancer topics: Liver cancer. http://www.cancer.gov/ cancertopics/types/liver (accessed Apr. 9, 2011).
178. Doll R, Hill AB. 1950. Smoking and carcinoma of the lung: preliminary report. Br Med J, 2, 739-48.
179. Leischow SJ, Djordjevic MV. 2004. Smoking reduction and tobacco-related cancers: the more things change, the more they stay the same. J Natl Cancer Inst, 96, 86-7.
180. Jones SC, Travers MJ, Hahn EJ, et al. 2006. Secondhand smoke and indoor public spaces in Paducah, Kentucky. J Ky Med Assoc, 104, 281-8.
181. Subramanian J, Govindan R. 2007. Lung cancer in never smokers: a review. J Clin Oncol, 25, 561-70.
182. Benowitz NL. 1992. Cigarette smoking and nicotine addiction. Med Clin North Am, 76, 415-37.
183. Moody PM. 1984. Human smoking patterns and smoke deliveries. Int J Addict, 19, 431-9.
184. Woo RS, Park EY, Shin MS, et al. 2002. Mechanism of nicotine-evoked release of 3Hnoradrenaline in human cerebral cortex slices. Br J Pharmacol, 137, 1063-70.
185. Frankish HM, Dryden S, Wang Q, Bing C, MacFarlane IA, Williams G. 1995. Nicotine administration reduces neuropeptide Y and neuropeptide Y mRNA concentrations in the rat hypothalamus: NPY may mediate nicotine’s effects on energy balance. Brain Res, 694, 139-46.
186. Cohen C, Pickworth WB, Henningfield JE. 1991. Cigarette smoking and addiction. Clin Chest Med, 12, 701-10.
187. Brunnemann KD, Hoffmann D. 1991. Analytical studies on tobacco-specific N-nitrosamines in tobacco and tobacco smoke. Crit Rev Toxicol, 21, 235-40.
188. Rabinoff M, Caskey N, Rissling A, Park C. 2007. Pharmacological and chemical effects of cigarette additives. Am J Public Health, 97, 1981-91.
189. Willems EW, Rambali B, Vleeming W, Opperhuizen A, van Amsterdam JG. 2006. Significance of ammonium compounds on nicotine exposure to cigarette smokers. Food Chem Toxicol, 44, 678-88.
190. Keithly L, Ferris WG, Cullen DM, Connolly GN. 2005. Industry research on the use and effects of levulinic acid: a case study in cigarette additives. Nicotine Tob Res, 7, 761-71.
191. Ezzati M, Lopez AD. 2003. Measuring the accumulated hazards of smoking: global and regional estimates for 2000. Tobacco Control, 12, 79-85.
192. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. 2002. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene, 21, 7435-51.
193. Rickert WS, Robinson JC, Bray DF, Rogers B, Collishaw NE. 1985. Characterization of tobacco products: a comparative study of the tar, nicotine, and carbon monoxide yields of cigars, manufactured cigarettes, and cigarettes made from fine-cut tobacco. Prev Med, 14, 226-33.
194. Muller FH. 1939. Tobacco use and lung carcinoma. Z Krebsforsch, 49, 57.
195. Berthiller J, Sasco AJ. 2005. Smoking (active or passive) in relation to fertility, medically assisted procreation and pregnancy. J Gynecol Obstet Biol Reprod (Paris), 1, 3547-54.
196. Tobacco-Free Kids: The Role of Tobacco in the United States. http://www.tobaccofreekids. org/facts_issues/toll_us/ (accessed Apr. 9, 2011).
197. Baker F, Ainsworth SR, et al. 2000. Health risks associated with cigar smoking. JAMA, 284, 735-40.
198. National Cancer Institute. Tobacco Control Research. http://cancercontrol.cancer.gov/ tcrb/monographs/20/index.html (accessed Apr. 9, 2011).
199. Liu P, Vikis HG, Lu Y, Wang Y, et al. 2010. Cumulative effect of multiple loci on genetic susceptibility to familial lung cancer. Cancer Epidemiol Biomarkers Prev, 19, 517-24.
200. National Cancer Institute. 2010. Cancer topics: Lung cancer. http://www.cancer.gov/ cancertopics/types/lung (accessed Apr. 9, 2011).
201. Bailey-Wilson JE, Amos CI, Pinney SM, Peterson GM, de Andrade M, et al. 2004. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet, 75, 460-74.
202. National Cancer Institute. 2010. Cancer topics: Smoking: Tobacco facts. http://www. cancer.gov/cancertopics/tobacco/smoking (accessed Apr. 9, 2011).
203. Lubin F, Chetrit A, Modan B, Freedman LS. 2006. Dietary intake changes and their association with ovarian cancer risk. J Nutr, 136, 2362-7.
204. Kushi LH, Mink PJ, Folsom AR, et al. 1999. Prospective study of diet and ovarian cancer. Am J Epidemiol, 149, 21-31.
205. Larsson SC, Holmberg L, Wolk A. 2004. Fruit and vegetable consumption in relation to ovarian cancer incidence: the Swedish Mammography Cohort. Br J Cancer, 90, 2167-70.
206. Seeger H, Wallwiener D, Kraemer E, Mueck AO. 2005. Estradiol metabolites are potent mitogenic substances for human ovarian cancer cells. Eur J Gynaecol Oncol, 26, 383-5.
207. Lancaster JM, Sayer RA, Blanchette C, et al. 2006. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer, 16, 1529-35.
208. Tworoger SS, Lee IM, Buring JE, Pollak MN, Hankinson SE. 2007. Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts. Cancer Epidemiol Biomarkers Prev, 16, 1691-5.
209. Schmeler KM, Lynch HT, Chen LM, et al. 2006. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med, 354, 261-9.
210. Holschneider CH, Berek JS. 2000. Ovarian cancer: epidemiology, biology and prognostic factors. Semin Surg Oncol, 19, 3-10.
211. Purdie DM, Bain CJ, Siskind V, et al. 2003. Ovulation and risk of epithelial ovarian cancer. Int J Cancer, 104, 228-32.
212. National Cancer Institute. 2010. Cancer topics: Endometrial cancer. http://www.cancer. gov/cancertopics/types/endometrial (accessed December 2010).
213. Ciernikova S, Tomka M, Kovac M, et al. 2006. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma, 53, 97-102.
214. Levine DA, Lin O, Barakat RR, et al. 2001. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol, 80, 395-8.
215. Preston DL, Ron E, Tokuoka S, et al. 2007. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiation Res, 168, 1-64.
216. Preston DL, Shimizu Y, Pierce DA. 2003. Studies of mortality of atomic bomb survivors. Radiation Res, 160, 381-407.
217. Melin A, Sparen P. 2007. The risk of cancer and the role of parity among women with endometrosis. Human Reprod, 22, i27-i28.
218. National Cancer Institute. 2010. Cancer topics: Ovarian cancer. http://www.cancer. gov/cancertopics/types/ovarian (accessed Apr. 7, 2011).
219. Michaud DS. 2004. Epidemiology of pancreatic cancer. Minerva Chir, 59, 99-111.
220. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. 2001. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA, 286, 921-9.
221. Muscat JE, Stellman SD, Hoffmann D, Wynder EL. 1997. Smoking and pancreatic cancer in men and women. Cancer Epidemiol Biomarkers Prev, 6, 15-19.
222. Klein AP, Brune KA, Petersen GM, et al. 2004. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res, 64, 2634-8.
223. Lowenfels AB, Maisonneuve P, Lankisch PG. 1999. Chronic pancreatitis and other risk factors for pancreatic cancer. Gastroenterol Clin North Am, 28, 673-85
224. Uygur-Bayramicli O, Dabak R, Orbay E, et al. 2007. Type 2 diabetes mellitus and CA 19-9 levels. World J Gastroenterol, 13, 5357-9.
225. Larsson SC, Bergkvist L, Wolk A. 2006. Consumption of sugar and sugar-sweetened foods and the risk of pancreatic cancer in a prospective study. Am J Clin Nutr, 84, 1171-6.
226. Alguacil J, Porta M, Benavides FG, et al. 2000. Occupation and pancreatic cancer in Spain: a case-control study based on job titles. PANKRAS II Study Group. Int J Epidemiol, 29, 1004-13.
227. Risch HA. 2003. Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst, 95, 948-60.
228. Anderson KE, Sinha R, Kulldorff M, et al. 2002. Meat intake and cooking techniques: associations with pancreatic cancer. Mutat Res, 506, 225-31.
229. Gallicchio L, Kouzis A, Genkinger JM, et al. 2006. Active cigarette smoking, household passive smoke exposure, and the risk of developing pancreatic cancer. Prev Med, 42, 200-5.
230. Hasan MM, Abbruzzese JL, Bondy ML, Wolff RA, et al. 2007. Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. Cancer, 109, 2547-56.
231. Li D, Xie K, Wolff R, Abbruzzese JL. 2004. Pancreatic cancer. Lancet, 363, 1049-57.
232. Pezzilli R, Casadei R, Morselli-Labate AM. 2009. Is type 2 diabetes a risk factor for pancreatic cancer? JOP. J Pancreas, 10(6), 705-6.
233. International Agency for Research on Cancer; GLOBOCAN. 2008. Cancer incidence and mortality worldwide. World predictions for pancreatic cancer, 2010. http://globocan.iarc.fr/burden.asp?selection_pop=220900&Text-p=World&selection_ cancer=22090&Text-c=Pancreas&pYear=2&type=1&window=1&submit=%A0Exec ute%A0 (accessed Apr. 7, 2011).
234. National Cancer Institute. 2010. Cancer topics: Pancreatic cancer. http://www.cancer. gov/cancertopics/types/pancreatic (accessed Apr. 13, 2011).
235. De Marzo AM, Meeker AK, Zha S, et al. 2003. Human prostate cancer precursors and pathobiology. Urology, 62 (suppl 1), 55-62.
236. Kwabi-Addo B, Chung W, Shen L, et al. 2007. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res, 13, 3796-802.
237. Zeegers MP, Kiemeney LA, Nieder AM, Ostrer H. 2004. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev, 13 (pt 1), 1765-71.
238. Palapattu GS, Sutcliffe S, Bastian PJ, et al. 2005. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis, 26, 1170-81.
239. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. 2000. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst, 92, 2009-17.
240. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. 1996. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst, 88, 1118-26.
241. De Marzo AM, Platz EA, Sutcliffe S, et al. 2007. Inflammation in prostate carcinogenesis. Nat Rev Cancer, 7, 256-69.
242. Huang WY, Hayes R, Pfeiffer R, et al. 2008. Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 17, 2374-81.
243. Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R. 2009. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol, 55, 864-73.
244. Ehrlichman RJ, Isaacs JT, Coffey DS. 1981. Differences in the effects of estradiol on dihydrotestosterone induced prostate growth of the castrated dog and rat. Invest Urol, 18, 466-70.
245. Mahapokai W, Xue Y, van Garderen E, et al. 2000. Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog. Prostate, 44, 40-8.
246. Asamoto M, Hokaiwado N, Cho YM, et al. 2001. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res, 61, 4693-700.
247. Jackson MA, Kovi J, Heshmat MY, et al. 1980 Characterization of prostatic carcinoma among blacks: a comparison between a low-incidence area, Ibadan, Nigeria, and a high-incidence area, Washington DC. Prostate, 1, 185-205.
248. Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, et al. 2009 Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agents Cancer, 4 (suppl 1), S2.
249. Gudmundsson J, Sulem P, Manolescu A, et al. 2007. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet, 39, 631-7.
250. National Cancer Institute. 2010. Cancer topics: Prostate cancer. http://www.cancer. gov/cancertopics/types/prostate (accessed Apr. 7, 2011).
251. National Center for Health Statistics, National Cancer Institute. 2010. SEER stat fact sheets: Melanoma of the skin. http://seer.cancer.gov/statfacts/html/melan.html (accessed Apr. 9, 2011).
252. Daya-Grosjean L, Sarasin A. 2005. The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. Mutat Res, 571, 43-56.
253. Wilson LD, Housman D, Smith BD. 2005. Merkel cell carcinoma: improved outcome with the addition of adjuvant therapy. J Clin Oncol, 23, 7236-7.
254. National Cancer Institute. 2010. Fact sheet: Cryosurgery in cancer treatment: Questions and answers. http://www.cancer.gov/cancertopics/factsheet/Therapy/cryosurgery (accessed Apr. 13, 2011).
255. Gorlin RJ. 1995. Nevoid basal cell carcinoma syndrome. Dermatol Clin, 13, 113-25.
256. Iftner A, Klug SJ, Garbe C, et al. 2003. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res, 63, 7515-9.
257. Curtin JA, Fridlyand J, Kageshita T, et al. 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med, 353, 2135-47.
258. Fears TR, Guerry D, Pfeiffer RM, et al. 2006. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol, 24, 3590-6.
259. Roewert-Huber J, Stockfleth E, Kerl H. 2007. Pathology and pathobiology of actinic (solar) keratosis·an update. Br J Dermatol, 157 (suppl 2), 18-20.
260. Staberg B, Wulf HC, Poulsen T, Klemp P, Brodthagen H. 1983. Carcinogenic effect of sequential artificial sunlight and UV-A irradiation in hairless mice. Consequences for solarium „therapy.‰ Arch Dermatol, 119, 641-3.
261. Bolshakov S, Walker CM, Strom SS, Selvan Ms, Clayman GL, El-Naggar A, et al. 2003. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin. Cancer Res, 9, 228-34.
262. Yang X, Pfeiffer RM, Goldstein AM. 2006. Influence of glutathione-S-transferase (GSTMI, GSTPI, GSTTI) and Cytochrome p450 (CYPIAi, CYP2D6) polymorphisms on numbers of basal cell carcinomas. J Med Genet, 43, e16.
263. Woo DK, Eide MJ. 2010. Tanning beds, skin cancer and vitamin D: an examination of the scientific evidence and public health implications. Dermatol Ther, 23, 61-71.
264. Berwick M. 2008. Are tanning beds “safe”? Human studies of melanoma. Pigment Cell Melanoma Res, 21, 517-9.
265. Feng H, Shuda M, Chang Y and Moore P. 2008 Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science, 319(5866), 1096-1100.
266. U.S. Environmental Protection Agency. 2010. SunWise program. Skin cancer facts. http://www.epa.gov/sunwise/background.html (accessed Mar. 16, 2011).
267. Waldron HA. 1983. A brief history of scrotal cancer. Br J Ind Med, 40, 390-401.
268. Siemiatycki J, Richardson L, Straif K, et al. 2004. Listing occupational carcinogens. Environ Health Perspect, 112, 1447-59.
269. Blair A, Rothman N, Zahm SH. 1999. Occupational cancer epidemiology in the coming decades. Scand J Work Environ Health, 25, 491-7.
270. Boffetta P. 2004. Epidemiology of environmental and occupational cancer. Oncogene, 23, 6392-403.
271. Baker DB, Landrigan PJ. 1990. Occupationally related disorders. Med Clin North AM, 74(2), 441-60.
272. Tola S. 1980. Occupational cancer of the urinary bladder. J Toxicol Environ Health, 6(5-6), 1253-60.
273. Gottschall EB. 2002. Occupational and environmental thoracic malignancies. J Thorac Imaging, 17(3), 189-97.
274. Bruske-Hohlfeld I. 2009. Environmental and occupational risk factors for lung cancer. Methods Mol Biol, 472, 3-23.
275. Sathia Kumar N, Delzell E, Amoateng-Adjepong Y, et al. 1997. Epidemiologic evidence on the relationship between mists containing sulfuric acid nd respiratory track cancer. Crit Rev Toxicol, 27, 233-51.
276. Kuntz HD, May B. 1980. Occupational liver diseases [in German]. MMW Munch Med Wochenschr, 122, 1059-62.
277. Gawkrodger DJ. 2004. Occupational skin cancers. Occup Med (Lond), 54, 458-63.
278. Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ. 2010. Exposure to benzene at work and the risk of leukemia: a systemic review and meta-analysis. Environ Health, 9, 31. http://www.cancer.gov/newsletter/cancer-and-the environment.
279. Michels KB. 2003. Nutritional epidemiology·past, present, future. Int J Epidemiol, 32, 486-8.
280. Doll R, Peto R. 1981. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst, 66, 1191-308.
281. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. 2003. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med, 348, 2599-608.
282. Foran JA, Carpenter DO, Hamilton MC, Knuth BA, Schwager SJ. 2005. Risk-based consumption advice for farmed Atlantic and wild Pacific salmon contaminated with dioxins and dioxin-like compounds. Environ Health Perspect, 113, 552-6.
283. Sinha R, Peters U, Cross AJ, et al. 2005. Meat, meat cooking methods and preservation, and risk for colorectal adenoma. Cancer Res, 65, 8034-41.
284. Ryan BM, Weir DG. 2001. Relevance of folate metabolism in the pathogenesis of colorectal cancer. J Lab Clin Med, 138, 164-76.
285. Kushi L, Giovannucci E. 2002. Dietary fat and cancer. Am J Med, 113 (suppl 9B), 63S-70S.
286. Curtin K, Bigler J, Slattery ML, Caan B, Potter JD, Ulrich CM. 2004. MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev, 13, 285-92.
287. Chen J, Stampfer MJ, Hough HL, et al. 1998. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res, 58, 3307-11.
288. Fleischauer AT, Arab L. 2001. Garlic and cancer: a critical review of the epidemiologic literature. J Nutr, 131 (suppl), 1032S-40S.
289. Campbell JK, Canene-Adams K, Lindshield BL, Boileau TW, Clinton S. K., Erdman JW Jr. 2004. Tomato phytochemicals and prostate cancer risk 4. J Nutr, 134 (suppl), 3486S-92S.
290. Hammami I, Amara S, Benahmed M, El May MV, Mauduit C. 2009. Chronic crude garlic-feeding modified adult male rat testicular markers: mechanisms of action. Reprod Biol Endocrinol, 7, 65.
291. Fleischauer AT, Poole C, Arab L. 2000. Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. Am J Clin Nutr, 72, 1047-52.
292. Arora DS, Kaur J. 1999. Antimicrobial activity of spices. Int J Antimicrob Agents, 12, 257-62.
293. Singh SV, Srivastava SK, Choi S, et al. 2005. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem, 280, 19911-24.
294. Hecht SS. 1999. Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. J Nutr, 129, 768S-74S.
295. Hakim IA, Harris RB, Brown S, et al. 2003. Effect of increased tea consumption on oxidative DNA damage among smokers: a randomized controlled study. J Nutr, 133 (suppl), 3303S-9S.
296. Fritz WA, Eltoum IE, Cotroneo MS, Lamartiniere CA. 2002. Genistein alters growth but is not toxic to the rat prostate. J Nutr, 132, 3007-11.
297. Zhou JR, Yu L, Mai Z, Blackburn GL. 2004. Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea bioactive components in mice. Int J Cancer, 108, 8-14.
298. Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH. 2004. Antioxidants block prostate cancer in lady transgenic mice. Cancer Res, 64, 5891-6.
299. Milner JA. 2004. Molecular targets for bioactive food components. J Nutr, 134 (suppl), 2492S-8S.
300. Pokharel YR, Han EH, Kim J, Oh SJ, et al. 2006. Potent protective effect of isoimperatorin against aflatoxin B1-inducible cytotoxicity in H4IIE cells: bifunctional effects on glutathione S-transferase and CYP1A. Carcinogenesis, 27, 2483-90.
301. Cho YA, Kim J, Park KS, Lim SY, et al. 2010. Effect of dietary soy intake on breast cancer risk according to menopause and hormone receptor status. Eur J Clin Nutr, 64, 924-32.
302. Wu AH, Yu MC, Tseng C-C, et al. 2009. Dietary patterns and breast cancer risk in Asian American women. Am J Clin Nutr, 89, 1145-54.
303. Lau TY, Lueg LK. 2006. Soya isoflavones suppress phorbal 12-myristate-13-acetateinduced cOX-2 expression in MCF-7 cells. Br J Nutr, 96, 169-76.
304. Navarro-Alarion M, Cabrera-Vique C. 2008. Selenium in food and the human body: a review. Sci Total Environ, 400, 115-41.
305. Liu X, Allen JD, Arnold JT, and Blackburn MR. 2008. Lycopene inhibits IGF-1 signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-1 production in co-cultured reactive stromal cells. Carcinogenesis, 29, 816-23.
306. National Institutes of Health, Office of Dietary Supplements. 2011. Dietary supplement fact sheet: Vitamin D. http://ods.od.nih.gov/factsheets/vitamind (accessed Apr. 7, 2011).
307. National Institutes of Health, Office of Dietary Supplements. 2009. Dietary supplement fact sheet: Selenium. http://ods.od.nih.gov/factsheets/selenium/ (accessed Apr. 7, 2011).
308. Peters U, Chatterjee N, Church TR, Mayo O, Sturup S, Foster CB, et al. 2006. High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program. Cancer Epidemiol Biomarkers Prev, 15, 315-20.
309. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 348, 1625-38.
310. Levine JA. 2004. Non-exercise activity thermogenesis (NEAT). Nutr Rev, 62 (suppl), S82-S97.
311. Wellman NS, Friedberg B. 2002. Causes and consequences of adult obesity: health, so-cial and economic impacts in the United States. Asia Pac J Clin Nutr, 11 (suppl), S705-S709.
312. Kennedy GC. 1953. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond B Biol Sci, 140, 578-96.
313. Gibbs J, Young RC, Smith GP. 1973. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol, 84, 488-95.
314. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. 2000. Central nervous system control of food intake. Nature, 404, 661-71.
315. Barsh GS, Schwartz MW. 2002. Genetic approaches to studying energy balance: perception and integration. Nat Rev Genet, 3, 589-600.
316. Campfield LA, Smith FJ, Burn P. 1998. Strategies and potential molecular targets for obesity treatment. Science, 280, 1383-7.
317. Wilson BD, Ollmann MM, Barsh GS. 1999. The role of agouti-related protein in regulating body weight. Mol Med Today, 5, 250-6.
318. Hofbauer KG. 2002. Molecular pathways to obesity. Int J Obes Relat Metab Disord, 26 (suppl), S18-S27.
319. Drewnowski A. 2004. Obesity and the food environment: dietary energy density and diet costs. Am J Prev Med, 27 (suppl), 154-62.
320. Friedenreich CM, Orenstein MR. 2002. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr, 132 (suppl), 3456S-64S.
321. Hursting SD, Lavigne JA, Berrigan D, et al. 2004. Diet-gene interactions in p53-deficient mice: insulin-like growth factor-1 as a mechanistic target. J Nutr, 134 (suppl), 2482S-6S.
322. Mahabir S, Baer DJ, Johnson LL, et al. 2006. Usefulness of body mass index as a sufficient adiposity measurement for sex hormone concentration associations in postmenopausal women. Cancer Epidemiol Biomarkers Prev, 15, 2502-7.
323. Wang Y, Jacobs EJ, Patel AV, et al. 2008. A prospective study of waist circumference and body mass index in relation to colorectal cancer incidence. Cancer Causes Control, 19, 783-92.
324. Wellen KE, Hotamisligil GS. 2005. Inflammation, stress, and diabetes. J Clin Invest, 115, 1111-9.
325. Hursting SD, Perkins SN, Brown CC, Haines DC, Phang JM. 1997. Calorie restriction induces a p53-independent delay of spontaneous carcinogenesis in p53-deficient and wild-type mice. Cancer Res, 57, 2843-6.
326. Bult MJ, van Dalen T, Muller AF. 2008. Surgical treatment of obesity. Eur J Endocrinol, 158, 135-45.
327. Mito N, Yoshino H, Hosoda T, Sato K. 2004. Analysis of the effect of leptin on immune function in vivo using diet-induced obese mice. J Endocrinol, 180, 167-73.
328. Pelleymounter MA. 1997. Leptin and the physiology of obesity. Current Pharmaceutical Design, 3, 85-98.
329. Ashizawa N, Yahata T, Quan J, Adachi S, Yoshihawa K and Tanaka K. 2010. Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecologic Oncology, 119, 65-69.
330. Chaplin DD. 2003. 1. Overview of the immune response. J Allergy Clin Immunol, 111 (suppl), S442-S459.
331. Madsen BE, Ramos EM, Boulard M, et al. 2008. Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer. PLoS One, 3, e2492.
332. Lan Q, Zheng T, Rothman N, et al. 2006. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood, 107, 4101-8.
333. Sharma RA, Browning MJ. 2005. Mechanisms of the self/non-self-survey in the defense against cancer: potential for chemoprevention? Crit Rev Oncol Hematol, 56, 5-22.
334. Lin WW, Karin M. 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest, 117, 1175-83.
335. Bernig T, Boersma BJ, Howe TM, et al. 2007. The mannose-binding lectin (MBL2) haplotype and breast cancer: an association study in African-American and Caucasian women. Carcinogenesis, 28, 828-36.
336. Stockbrugger RW. 1999. Nonsteroidal anti-inflammatory drugs (NSAIDs) in the prevention of colorectal cancer. Eur J Cancer Prev, 8 (suppl), S21-S25.
337. Chew BP, Park JS. 2004. Carotenoid action on the immune response. J Nutr, 134 (suppl), 257S-61S.
338. Xue L, Pestka JJ, Li M, Firestone GL, Bjeldanes LF. 2008. 3, 3′-Diindolylmethane stimulates murine immune function in vitro and in vivo. J Nutr Biochem, 19, 336-44.
339. Pedersen BK, Hoffman-Goetz L. 2000. Exercise and the immune system: regulation, integration, and adaptation. Physiol Rev, 80, 1055-81.
340. Barak Y. 2006. The immune system and happiness. Autoimmun Rev, 5, 523-7.
341. Cohen S, Alper CM, Doyle WJ, Treanor JJ, Turner RB. 2006. Positive emotional style predicts resistance to illness after experimental exposure to rhinovirus or influenza a virus. Psychosom Med, 68, 809-15.
342. Glaser R, Kennedy S, Lafuse WP, et al. 1990. Psychological stress-induced modulation of interleukin 2 receptor gene expression and interleukin 2 production in peripheral blood leukocytes. Arch Gen Psychiatry, 47, 707-12.
343. Galbo H. 1983. Hormonal and Metabolic Adaptation to Exercise. New York, NY: Thieme Verlag.
344. Volek JE, Kramer WJ, Bush JA, et al. 1997. Testosterone and cortisol in relationship to dietary nutrients and resistance exercise. J Appl Physiol, 82, 49-54.
345. Kujala UM, Alen M, Huhtaniemi IT. 1990. Gonadotrophin-releasing hormone and human chorionic gonadotrophin tests reveal that both hypothalamic and testicular endocrine functions are suppressed during acute prolonged physical exercise. Clin Endocrinol, 33, 219-25.
346. Ryden M, Hedback B, Jonasson L. 2009. Does stress reduction change the levels of cortisol secretion in patients with coronary artery disease? J Cardiopulmonary Rehab Prev, 29, 314-17.
347. Gates TJ. 2001. Screening for cancer: Evaluating the evidence. Am Fam Physician, 63, 513-22.
348. Kwabi-Addo B, Ozen M, Ittmann M. 2004. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer, 11, 709-24.
349. Yin M, Bastacky S, Chandran U, Becich MJ, Dhir R. 2008. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol, 179, 892-5.
350. Hessels D, Verhaegh GW, Schalken JA, Witjes JA. 2004. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn, 4, 513-26.
351. Austoker J. 1994. Screening for ovarian, prostatic, and testicular cancers. BMJ, 309, 315-20.
352. Schroder FH, Hugosson J, Roobol MJ, et al. 2009. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med, 360, 1320-8.
353. Walter LC, Bertenthal D, Lindquist K, Konety BR. 2006. PSA screening among elderly men with limited life expectancies. JAMA, 296, 2336-42.
354. Green BB, Taplin SH. 2003. Breast cancer screening controversies. J Am Board Fam Pract, 16, 233-41.
355. Shen Y, Parmigiani G. 2005. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations. Cancer Epidemiol Biomarkers Prev, 14, 529-32.
356. Smith JJ, Berg CD. 2008. Lung cancer screening: promise and pitfalls. Semin Oncol Nurs, 24, 9-15.
357. Beane J, Sebastiani P, Whitfield TH, et al. 2008. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res (Phila Pa), 1, 56-64.
358. Schiffman M, Castle PE. 2005. The promise of global cervical-cancer prevention. N Engl J Med, 353, 2101-4.
359. Wallace MB, Kemp JA, Trnka YM, Donovan JM, Farraye FA. 1998. Is colonoscopy indicated for small adenomas found by screening flexible sigmoidoscopy? Ann Intern Med, 129, 273-8.
360. Chan-Smutko G, Patel D, Shannon KM, Ryan PD. 2008. Professional challenges in cancer genetic testing: who is the patient? Oncologist, 13, 232-8.
361. Wakefield CE, Meiser B, Homewood J, Ward R, O’Donnell S, Kirk J. 2008. Randomized trial of a decision aid for individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk. Cancer, 113, 956-65.
362. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. 1999. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet, 64, 963-70.
363. Hudson KL. 2007. Prohibiting genetic discrimination. N Engl J Med, 356, 2021-3.
364. Michels KB, Giovannucci E, Chan AT, Singhania R, Fuchs CS, Willett WC. 2006. Fruit and vegetable consumption and colorectal adenomas in the Nurses’ Health Study. Cancer Res, 66, 3942-53.
365. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. 2007. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA, 297, 842-57.
366. Lee SH, Oe T, Blair IA. 2001. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science, 292, 2083-6.
367. Feiz HR, Mobarhan S. 2002. Does vitamin C intake slow the progression of gastric cancer in Helicobacter pylori-infected populations? Nutr Rev, 60, 34-6.
368. Proteggente AR, Rehman A, Halliwell B, Rice-Evans CA. 2000. Potential problems of ascorbate and iron supplementation: pro-oxidant effect in vivo? Biochem Biophys Res Commun, 277, 535-40.
369. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. 2006. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med, 354, 684-96.
370. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. 2007. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr, 85, 1586-91.
371. Ahn J, Peters U, Albanes D, et al. 2008. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst, 100, 796-804.
372. Davis CD. 2008. Vitamin D and cancer: current dilemmas and future research needs. Am J Clin Nutr, 88 (suppl), 565S-9S.
373. Moan J, Porojnicu AC, Dahlback A, Setlow RB. 2008. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc Natl Acad Sci, USA, 105, 668-73.
374. Hercberg S. 2005. The history of beta-carotene and cancers: from observational to intervention studies. What lessons can be drawn for future research on polyphenols? Am J Clin Nutr, 81 (suppl), 218S-22S.
375. Messina MJ, Wood CE. 2008. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J, 7, 17.
376. Iwasaki M, Inoue M, Otani T, et al. 2008. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol, 26, 1677-83.
377. Park Y, Hunter DJ, Spiegelman D, et al. 2005. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA, 294, 2849-57.
378. Lupton JR. 2004. Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr, 134, 479-82.
379. Chung FL, Schwartz J, Herzog CR, Yang YM. 2003. Tea and cancer prevention: studies in animals and humans. J Nutr, 133, 3268S-74S.
380. United States Department of Agriculture, Economic Research Service. 2010. Adoption of genetically engineered crops in the U.S. http://www.ers.usda.gov/Data/Biotech Crops/ (accessed Jan. 3, 2011).
381. Union of Concerned Scientists. 2002. Risks of genetic engineering. http://www.ucsusa. org/food_and_agriculture/science:and_impacts/impacts_genetic_engineering/risksof-genetic-engineering.html (accessed Jan. 4, 2011).
382. Dona A, Arvanitoyannis IS. 2009. Health risks of genetically modified foods. Crit Rev Food Sci Nutr, 49, 2, 164-75.
383. Bakshi A. 2003. Potential adverse health effects of genetically modified crops. J Toxicol Environ Health B Crit Rev, 6, 211-25.
384. Lemaux PG. 2008. Genetically engineered plants and foods: a scientist’s analysis of the issues (Part I). Annu Rev Plant Biol, 59, 771-812.
385. Benedet JL, Anderson GH, Matisic JP. 1992. A comprehensive program for cervical cancer detection and management. Am J Obstet Gynecol, 166, 1254-9.
386. Henson DE, Block G, Levine M. 1991. Ascorbic acid: biologic functions and relation to cancer. J Natl Cancer Inst, 146, 231-43.
387. Duarte TL, Lunec J. 2005. Review: when is an antioxidant not an antioxidant: a review of novel actions and reactions of vitamin C. Free Radic Res, 39, 671-86.
388. Carr A, Frei B. 1999. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J, 13, 1007-24.
389. Zeeb H, Greinert R. 2010. The role of vitamin D in cancer prevention. Deutsches Arzteblatt International, 107, 638-43.
390. Affenito SG, Kerstetter J. 1999. Position of the American Dietetic Association and Dietitians of Canada: Women’s Health and Nutrition. J Am Diet Assoc, 99, 738-51.
391. Duffy C, Perez K, Partridge A. 2007. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin, 57, 260-77.
392. Maliakal PP, Coville PF, Wanwimolruk S. 2001. Tea consumption modulates hepatic drug metabolising enzymes in Wistar rats. J Pharm Pharmacol, 53; 4, 569-77.
393. Khan SG, Katiyar SK, Agarwal R, Mukhtar H. 1992. Enhancement of anti-oxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: possible role in cancer chemoprevention. Cancer Res, 52, 4050-2.
394. Yang CS, Liao J, Yang GY, Lu G. 2005. Inhibition of lung tumorigenesis by tea. Exp Lung Res, 31, 135-44.
395. Sadava D, Whitlock E, Kane SE. 2007. The green tea polyphenol, epigallacatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun, 360, 233-7.
396. Zheng W, Doyle TJ, Kushi LH, Sellers TA, Hong CP, Folsom AR. 1996. Tea consumption and cancer incidence in a prospective cohort study of postmenopausal women. Am J Epidemiol, 144, 175-82.
397. Nagano J, Kono S, Preston DL, Mabuchi K. 2001. A prospective study of green tea consumption and cancer incidence. Hiroshima and Nagasaki (Japan). Cancer Causes Control, 12, 501-8.
398. Li Q, Kakizaki M, Kuriyama S, et al. 2008. Green tea consumption and lung cancer risk: the Ohsaki study. Br J Cancer, 99, 1179-84.
399. Mirick DK, Davis S, Thomas DB. 2002. Antiperspirant use and the risk of breast cancer. J Natl Cancer Inst, 94(20), 157-80.
400. Cancer Research UK. 2011. Cancer questions and answers: Deodorants, antiperspirants and breast cancer. http://www.cancerhelp.org.uk/about-cancer/cancer-questions/ deodorants-antiperspirants-and-breast-cancer (accessed Dec. 10, 2010).
401. Cancer and the environment: what you need to know; what you can do, August 2003, National Cancer Institute, U.S. Department of Health and Human Services.
402. Alavanja MCR, Dosemeci M, Samanic C, Lubin J, et al. 2004. Pesticides and lung cancer risk in the agricultural health study cohort. Am J Epidemiol, 160, 876-85.
403. National Cancer Institute. 2008. Psychological stress and cancer: Questions and answers. http://www.cancer.gov/cancertopics/factsheet/Risk/stress (accessed Jan. 5, 2011).
404. Spilsberg B, Rundberget T, Johannessen L, Kristoffersen A, Holst-Jensen A, Berdal K. 2010. Detection of food-derived damaged nucleosides with possible adverse effects on human health using a global adductomics approach. J Agric Food Chem, 58, 6370-5.
405. National Cancer Institute. 2009. Artificial sweeteners and cancer. http://www.cancer. gov/cancertopics/factsheet/Risk/artificial-sweeteners#ref1 (accessed Dec. 9, 2010).
406. The INTERPHONE Study Group. 2010. Brain tumour risk in relation to mobile telephone use: Results of the INTERPHONE international case-control study. Int J Epidemiol, published online ahead of print May 17, 2010.
407. Lonn S, Ahlbom A, Hall P, Feychting M. 2004 Mobile phone use and the risk of acoustic neuroma. Epidemiology, 15(6), 653-9.
408. Ahlbom A, Day N, Feychting M, et al. 2000. A pooled analysis of magnetic fields and childhood leukaemia. Br J Cancer, 83(5), 692-8.
409. Kheifets L, Ahlbom A, Crespi CM, et al. 2010. Pooled analysis of recent studies on magnetic fields and childhood leukemia. Br J Cancer, 103, 1128-35.
410. Linet MS, Hatch EE, Kleinerman RA, et al. 1997. Residential exposure to magnetic fields and acute lymphoblastic leukemia in children. New Engl J Med, 337(1), 1-7.
411. He K, Zhao L, Daviglus ML, et al. 2008. Association of monosodium glutamate intake with overweight in Chinese adults: the INTERMAP study. Obesity, 16, 1875-80.
412. Geha RS, Beiser A, Ren C, Patterson R, et al. 2000. Review of alleged reaction to monosodium glutamate and outcome of a multicenter double-blind placebo-controlled study. J Nutr, 130, 1058S-62S.
413. Freeman M. 2006. Reconsidering the effects of monosodium glutamate: a literature review. J Am Acad Nurse Pract, 18, 482-6.
414. Jinap S, Hajeb P. 2010 Glutamate: Its applications in food and contribution to health. Appetite, 55, 1-10.
415. Peters JC, Lawson KD, Middleton SJ, et al. 1997. Assessment of the nutritional effects of olestra, a nonabsorbed fat replacement: summary. J Nutr, 127, 1719S-28S.
416. Prince DM, Welschenbach MA. 1998. Olestra: a new food additive. J Am Diet Assoc, 98, 565-9.
417. Neuhouser ML, Rock CL, Kristal AR, et al. 2006. Olestra is associated with slight reductions in serum carotenoids but does not markedly influence serum fat-soluble vitamin concentrations. Am J Clin Nutr, 83, 624-31.
418. Levine A. 1997. Food fight in Indianapolis. U.S. News & World Report, 5, 53-4.
419. Sandler RS, Zorich NL, Filloon TG, et al. 1999. Gastrointestinal symptoms in 3181 volunteers ingesting snack foods containing olestra or triglycerides. Ann Intern Med, 130, 253-61.
420. Centers for Disease Control and Prevention. 2009. Irradiation of food: Frequently asked questions. http://www.cdc.gov/nczved/divisions/dfbmd/diseases/irradiation_ food/(accessed Dec. 17, 2010).
421. Centers for Disease Control and Prevention. 2011. CDC estimates of foodborne illness in the United States. http://www.cdc.gov/foodborneburden/2011-foodborne-estimates. html(accessed Dec. 17, 2010).
422. Farkas J. 1998. Irradiation as a method for decontaminating food: A review. Int J Food Microbiol, 44, 189-204.
423. Gosse RF, Hartwig DH, Miesch ME, et al. 2002. Food-borne radiolytic compounds (2-alkylcyclobutanones) may promote experimental colon carcinogenesis. Nutr Cancer, 44, 189-191.
424. Sommers CH. 2003. 2-Dodecyclobutanone does not induce mutations in the Escherichia coli tryptophan reverse mutation assay. J Agric Food Chem, 51, 6367-70.
425. Wood OB, Bruhn CM. 2000. Position of the American Dietetic Association: Food irradiation. J Am Diet Assoc, 100, 246-53.
426. Johansen C, Boice JD, McLaughlin JK, et al. 2001. Cellular telephones and cancer·a nationwide cohort study in Denmark. JNCI, 93, 203-7.
427. Schuz J, Jacobson R, Olsen JH, et al. 2006. Cellular telephone use and cancer risk: Update of a nationwide Danish cohort. JNCI, 98, 1707-13.
428. Sadetzki S, Chetrit A, Freedman L, et al. 2005. Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat Res, 163, 424-32.
429. Kundi M. 2009. The controversy about a possible relationship between mobile phone use and cancer. Environ Health Perspect, 117, 316-24.
430. Malagoli C, Fabbi S, Teggi S, et al. 2010. Risk of hematological malignancies associated with magnetic fields exposure from power lines: A case-control study in two municipalities of northern Italy. Environmental Health, 9, 16-23.
431. Kroll ME, Swanson J, Vincent TJ, Draper GJ. 2010. Childhood cancer and magnetic fields from high-voltage power lines in England and Wales: A case-control study. Br J Cancer, 103, 1122-7.
432. Fews AP, Henshaw DL, Wilding RJ, Keitch PA. 1999. Corona ions from powerlines and increased exposure to pollutant aerosols. Int. J Radiat Biol, 75, 1523-31.
433. Holden RJ, Pakula JS, et al. 1998. An immunological model connecting the pathogenesis of stress, depression and carcinoma. Med Hypotheses, 51, 309-14.
434. Darbre PD. 2009. Underarm antiperspirants/deodorants and breast cancer. Breast Cancer Res, 11, S5.
435. Clapp RW, Howe GK, Jacobs MM. 2005. Environmental and occupational causes of cancer: a review of scientific literature. Lowell Center for Sustainable Production. http://www.healthyenvironmentforkids.ca/sites/healthyenvironmentforkids.ca/files/ cpche-resources/Cancer_and_the_Environment.pdf (accessed Apr. 10, 2011).
436. U.S. Preventive Services Task Force Recommendation Statement 2009. Screening for breast cancer. Ann Intern Med, 151, 716-26.
437. Roos PH, Jakubowski N. 2010. Methods for the discovery of low-abundance biomarkers for urinary bladder cancer in biological fluids. Bioanalysis, 2(2), 295-309.
438. Obermayr E, Sanchez-Cabo F, Tea MK, et al. 2010. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer, 10, 666.
439. Rosas SL, Koch W, da Costa Carvalho MG, et al. 2001. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res, 61, 939-42.
440. CBC News. 2011. Blood test for cancer a step nearer. The Associated Press. http:// www.cbc.ca/canada/british-columbia/story/2011/01/03/health-cancer-blood-test. html#ixzz1A0qxPVhd (accessed January 2011).
441. Nagrath S, Sequist LV, Maheswaran S, et al. 2007. Isolation of rare circulating tumor cells in cancer patients by microchip technology. Nature, 450, 1235-9.
442. The American Cancer Society. 2009. Fruits and vegetables: Do you get enough? http:// www.cancer.org/Healthy/EatHealthyGetActive/EatHealthy/fruits-and-vegetables-doyou-get-enough (accessed Jan. 4, 2011).
443. Block G. 1991. Vitamin C and cancer prevention: The epidemiologic evidence. Am J Clin Nutr, 53, 270S-282S.
444. National Cancer Institute. Selenium and vitamin E cancer prevention trial (SELECT), http://www.cancer.gov/newscenter/qa/2008/selectqa (accessed May 2, 2011).
445. Messina M, Persky V, Setchell KD, Barnes S. 1994. Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr Cancer, 21, 113-31.
446. Phillips GO and Cui SW. 2011. An introduction: Evolution and finalization of the regulatory definition of dietary fiber. Food Hydrocolloids, 25, 139-43.
447. Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T et al. 2003. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): An observational study. Lancet, 361, 1496-501.
448. Peters U, Sinha R, Chatterjee N, Subar AF, Ziegler RG, Kulldorff M., et al. 2003. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet, 361, 1491-5.
449. The American Cancer Society. 2011. Aspartame. www.cancer.org/Cancer/Cancer-Causes/OtherCarcinogens/AtHome/aspartame (accessed Apr. 6, 2011).
450. Cancer Research UK. 2006. Cancer news: EU rules out aspartame cancer risk. http://info.cancerresearchuk.org/news/archive/cancernews/2006-05-09-eu-rules-outaspartame-cancer-risk (accessed Apr. 6, 2011).
451. National Cancer Institute. 2006. Fact sheet: Aspartame and cancer. http://www.cancer. gov/cancertopics/factsheet/Risk/aspartame (accessed Apr. 6, 2011).
452. U.S. Department of Agriculture. 2005. Dietary guidelines for Americans. http://www. health.gov/dietaryguidelines/dga2005/document/html/chapter5.htm (accessed Dec. 1, 2010).
453. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, and Heaney RP. 2008. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr, 85, 1586-91.
454. Correa P, Fontham ET, Bravo LE, Ruiz B, Zarama G, Realpe JL, et al. 2000. Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J. Natl Cancer Inst, 92, 1881-88.
455. National Institutes of Health, Office of Dietary Supplements. 2011. Dietary supplement fact sheet: Vitamin D. http://ods.od.nih.gov/factsheets/VitaminD (accessed Jan. 7, 2011).
456. International Agency for Research on Cancer. 2001. Press Release: IARC finds limited evidence that residential magnetic fields increase the risk of childhood leukemia. http://www.iarc.fr/en/media-centre/pr/2001/pr136.html (accessed Mar. 16, 2011).
457. Cancer Research UK. 2009. Dietary factors and breast cancer. http://www. cancerhelp.org.uk/type/breast-cancer/about/diet/dietary-factors-and-breast-cancer# pesticides (accessed Jan. 3, 2011).
458. Cancer Research UK. 2010. Pesticides and cancer. http://info.cancerresearchuk.org/ healthyliving/cancercontroversies/pesticides/(accessed Jan. 3, 2011).
459. National Cancer Institute.2010. Lung cancer. www.cancer.gov/cancertopics/types/ lung(accessed Apr. 7, 2011).
460. American Cancer Society. 2011. Colorectal cancer overview: How many people get colorectal cancer? http://www.cancer.org/Cancer/ColonandRectumCancer/Overview Guide/colorectal-cancer-overview-key-statistics (accessed Apr. 7, 2011).
461. World Cancer Research Fund/American Institute for Cancer Research. 1997. Food research and the prevention of cancer: A global perspective. www.aicr.org/site/ News2?page=NewsArticle&id=13067 (accessed May 2, 2011).
462. Xu J, Kibel AS, Hu JJ, et al. 2009. Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev, 18, 2145-9.
463. Ambs S, Marincola FM, Thurin M. 2008. Profiling of immune response to guide cancer diagnosis, prognosis, and prediction of therapy. Cancer Res, 68, 4031-3.
464. Yeatman TJ, Mule J, Dalton WS, Sullivan D. 2008. On the eve of personalized medicine in oncology. Cancer Res, 68, 7250-2.
465. Weinstein IB, Case K. 2008. The history of cancer research: introducing an AACR centennial series. Cancer Res, 68, 6861-2.
466. GLOBOCAN 2008. 2010. Cancer incidence and mortality worldwide, estimated cancer deaths for 2010. http://globocan.iarc.fr/burden.asp?selection_pop=220900&Text-p= World&selection_cancer=280&Text-c=All+cancers+excl.+non-melanoma+skin+c ancer&pYear=2&type=1&window=1&submit=%A0Execute%A0 (accessed Apr. 6, 2011).
467. World Health Organization. 2011. Cancer fact sheet number 297. http://www.who.int/ mediacentre/factsheets/fs297/en/ (accessed Apr. 6, 2011).
468. National Institutes of Health (U.S.). 2007. Biological sciences curriculum study: Cancer and society. Bethesda (MD) Bookshelf ID: NBK20362. http://www.ncbi.nlm.nih. gov/books/NBK20362/ (accessed Mar. 18, 2011).
469. National Cancer Institute. 2008. Annual report to the nation finds declines in cancer incidence and death rates. http://www.cancer.gov/newscenter/pressreleases/2008/report nation2008release (accessed Apr. 14, 2011).
470. National Cancer Institute. Cancer Genome Anatomy Project. http://www.ncbi.nlm. nih.gov/ncicgap/ (accessed Apr. 7, 2011).
471. National Cancer Institute. 2010. TAILORx Breast Cancer Trial http://www.cancer. gov/clinicaltrials/noteworthy-trials/tailorx (accessed Apr. 7, 2011).
472. Moffitt Cancer Center. 2011. Overview: What is total cancer care? http://www.moffitt. org/totalcancercare (accessed Apr. 7, 2011).
473. UN News Center. 2010. New cancer cases and deaths to double by 2030. http://www. un.org/apps/news/story.asp?NewsID=34888&Cr=world+health+organization&Cr1 (accessed Apr. 7, 2011).